What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
Hidekazu Suzuki spends much of his time researching Internal medicine, Helicobacter pylori, Gastroenterology, Endocrinology and Immunology.
Internal medicine is frequently linked to Surgery in his study.
Hidekazu Suzuki has researched Helicobacter pylori in several fields, including Stomach, Gastric mucosa and Microbiology.
His work focuses on many connections between Gastric mucosa and other disciplines, such as Pathology, that overlap with his field of interest in Molecular biology.
His Gastroenterology research is multidisciplinary, relying on both Postprandial, Surgical oncology, Clinical trial and Disease.
His Endocrinology research includes themes of Xanthine dehydrogenase and Cell adhesion.
His most cited work include:
- Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (4170 citations)
- Rome IV - Gastroduodenal Disorders. (460 citations)
- Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3–kinase (362 citations)
What are the main themes of his work throughout his whole career to date?
Hidekazu Suzuki focuses on Internal medicine, Gastroenterology, Helicobacter pylori, Pathology and Endocrinology.
As part of the same scientific family, Hidekazu Suzuki usually focuses on Internal medicine, concentrating on Oncology and intersecting with Chemotherapy.
He interconnects Amoxicillin and Disease in the investigation of issues within Gastroenterology.
His study in Helicobacter pylori is interdisciplinary in nature, drawing from both Stomach, Gastric mucosa, Immunology and Microbiology.
Hidekazu Suzuki combines topics linked to Molecular biology with his work on Gastric mucosa.
His studies deal with areas such as Nivolumab and Performance status as well as Lung cancer.
He most often published in these fields:
- Internal medicine (49.27%)
- Gastroenterology (25.24%)
- Helicobacter pylori (25.12%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (49.27%)
- Gastroenterology (25.24%)
- Lung cancer (8.90%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Gastroenterology, Lung cancer, Oncology and Helicobacter pylori.
Hidekazu Suzuki combines subjects such as Cancer, Regimen, Atrophy and Confidence interval with his study of Gastroenterology.
His research integrates issues of Helicobacter and Gastric mucosa in his study of Cancer.
His study on Lung cancer also encompasses disciplines like
- Nivolumab and related Interstitial lung disease,
- Malignant pleural effusion most often made with reference to Hazard ratio.
His Oncology study deals with Epidermal growth factor receptor intersecting with Adenocarcinoma and Lung.
He works mostly in the field of Helicobacter pylori, limiting it down to topics relating to Amoxicillin and, in certain cases, Clarithromycin, as a part of the same area of interest.
Between 2016 and 2021, his most popular works were:
- World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. (59 citations)
- Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial. (49 citations)
- Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer (47 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
Hidekazu Suzuki mostly deals with Internal medicine, Gastroenterology, Lung cancer, Helicobacter pylori and Oncology.
As part of his studies on Internal medicine, Hidekazu Suzuki often connects relevant areas like Metronidazole.
His Gastroenterology study combines topics from a wide range of disciplines, such as Cancer, Disease, Hyaluronic acid and Confidence interval.
His work carried out in the field of Lung cancer brings together such families of science as Progression-free survival, Prospective cohort study, Multicenter trial, Hazard ratio and Nivolumab.
His Helicobacter pylori study integrates concerns from other disciplines, such as Amoxicillin, Sitafloxacin and Zoonotic bacteria, Antibiotic resistance.
His Oncology research incorporates themes from Metastasis, Lung and Adenocarcinoma.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
